Urinary tract infections (UTIs) are caused by a wide range of pathogens, constituting one of the most important public health problems worldwide (
1). UTIs can affect both genders in all age groups. However, some individuals are at higher risk. In general, adult women are 30 times more likely to develop UTI, with 40% of all of them experiencing it at some point in their lives (
2,
3). UTIs are reported to be the second most commonly treated infection in primary care and are the most common infection seen in a hospital setting, encompassing 40% of all hospital-acquired infections (
4,
5). Microbial agents can infect any part of the genitourinary system and are clinically categorized as complicated or uncomplicated. In healthy patients and in the absence of structural abnormalities, uncomplicated UTIs are further differentiated as either upper or lower, typically seen as pyelonephritis and cystitis, respectively (
6). These patients typically present with dysuria, urgency, urinary frequency, fever, and flank pain (
7). Complicated UTIs are those seen during pregnancy, in patients with renal failure or transplantation, or in immunosuppressed patients but are most commonly associated with indwelling catheters (
8). Diagnosis is based on signs and symptoms of infection and urine analysis (UA), with urine culture (UC) typically being reserved for complicated UTIs (
9). The treatment of choice in UTIs depends on whether it is complicated or not, with antibiotics such as ciprofloxacin and ampicillin being the most commonly prescribed (
2,
10). However, treatment is complicated with increasing rates of antibiotic resistance and the emergence of multidrug-resistant pathogens. Thus, it is important to evaluate the frequency of these resistances in different microbial agents, to further understand their mechanism and to provide adequate treatment (
11).